pembrolizumab,cg0070
cg oncology,merck
['pembro', 'cg0070', 'cg onco']
#sitc22 updates: cg oncology continues to demonstrate positive data from the ph2 core study of cg0070 (ov) + pembro in bcg-unresponsive nmibc pts (cr rate 87%), more than double cr rate as seen with cpis - full readout expected next year #bladdercancer #oncolyticvirus #oncology 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.